Results 91 to 100 of about 27,075 (224)

Evaluation of Olaparib Tablet Safety and Pharmacokinetics in Healthy Chinese Male Subjects [PDF]

Ruihua Dong,1,* Jingcheng Chen,1,* Nini Guo,2 Yingying Yang,2 Jingxuan Wu,1 Xiaoru Wang,2 Yuqin Song,1 Xueyuan Zhang2 1Phase I Clinical Trial Laboratory, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China;
Guo N, Wu J, Yang Y, Chen J, Zhang X, Wang X, Dong R, Song Y   +7 more
core  

PCN95 cost-effectiveness analysis of germline BRCA mutation testing and olaparib treatment in metastatic breast cancer: an evaluation of codependent technologies

, 2019
Objectives: Genetic testing for a germline BRCA mutation in women with HER2-negative metastatic breast cancer (MBC) can guide targeted treatment with PARP inhibitors (e.g.
Tuffaha, H., Tuffaha, H, Scuffham, P, Scuffham, P.   +3 more
core   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B)

Contemporary Clinical Trials Communications
Background: Pharmacokinetic (PK) boosting is the intentional use of a drug-drug interaction to enhance systemic drug exposure. PK boosting of the anticancer drug olaparib, a CYP3A-substrate, has the potential to reduce PK variability, side effects and ...
Joanneke K. Overbeek, Niels A.D. Guchelaar, Ma Ida Mohmaed Ali, Muriëlle Sark, Carolien Hovenier, Wietske Kievit, Marjolijn J.L. Ligtenberg, Petronella B. Ottevanger, Haiko J. Bloemendal, Stijn L.W. Koolen, Ron H.J. Mathijssen, Ingrid A. Boere, Alwin D.R. Huitema, Gabe S. Sonke, Frans L. Opdam, Rob ter Heine, Nielka P. van Erp   +16 more
doaj   +1 more source

Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer [PDF]

, 2018
BACKGROUND: Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment with surgery and platinum-based chemotherapy.
Oza, Amit, Bradley, William, Banerjee, Susana, Scambia, Giovanni, Colombo, Nicoletta, Sonke, Gabe S., Mathews, Cara, Oaknin, Ana, Bloomfield, Ralph, Scambia, G., Kim, Byoung-Gie, Gonzalez-Martin, Antonio, Lowe, Elizabeth S., Moore, Kathleen, Aghajanian, Carol, DiSilvestro, Paul, Lisyanskaya, Alla, Floquet, Anne, Liu, Joyce, Friedlander, Michael, Leary, Alexandra, Gourley, Charlie   +21 more
core   +1 more source

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials

, 2019
Jiao Ma,1 Hongyong Deng,2 Jiajia Li,1 Shaopu Hu,3 Yanping Yang,3 Sheng Liu,1 Xianghui Han11Institute of Chinese Traditional Surgery, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, People’s ...
Hu S, Li J, Yang Y, Han X, Ma J, Liu S, Deng H   +6 more
core  

A guide to transcriptional cyclin‐dependent kinases in cancer

The FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin, Salla Kyheröinen, Ricky W. Johnstone   +2 more
wiley   +1 more source

Lynparza (olaparib): novo tarčno zdravilo pri raku jajčnikov [PDF]

, 2016
A new medicine for targeted treatment of patients with recurring serous ovarian or primary peritoneal serous carcinoma (PPSC), who have a mutation of BRCA1/2 genes (somatic mutation), was recently registered in the EU – LynparzaTM (olaparib).
Krajc, Mateja, Škof, Erik
core   +1 more source

Value for money of putting precision into practice: Germline genetic testing to guide olaparib treatment in HER2-negative metastatic breast cancer

, 2019
Aim: Genetic testing for germline BRCA mutation in women with HER2‐negative metastatic breast cancer (MBC) can guide targeted treatment with poly‐ADP‐ribose polymerase (PARP) inhibitors (eg olaparib) and inform cancer prevention strategies (eg risk ...
Scuffham, Paul, Tuffaha, Haitham
core   +1 more source